Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)
2022 · European Journal of Cancer · 3 citations
https://doi.org/10.1016/s0959-8049(22)01000-0